Analyst Note
| Preston Caldwell |Core Laboratories reported fourth-quarter revenue up 8% sequentially, mainly due to improved U.S. shale activity. Adjusted operating income only improved to $13 million from $12.3 million in the prior quarter (implying 9% incrementals), which management attributed to various operational delays caused by COVID-19. Our fair value estimate and wide moat rating are unchanged following the results.